MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-025-07220-3

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2025

HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.

Gao Yuan, Yin Lei, Duan Xiaojiang, Fu Zijian, Liu Qian, Chen Jinzhi, Xin Ling, Zhu Xiaojuan, Xiang Hongyu, Xu Ling, Ye Jingming, Liu Meng

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with 18F-FDG PET/CT.

METHODS

In this prospective study conducted from May 2024 to Jan 2025, participants with newly diagnosed breast cancer underwent both 68Ga-HER2-affibody and 18F-FDG PET/CT examinations. The relationship between PET parameters (such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor-to-background SUV ratio (TBR)) and HER2 expression statuses (HER2-zero, -low and -positive) was analyzed.

RESULTS

A total of 57 female participants (58 primary lesions) with newly diagnosed breast cancer were included. In the paired comparison of 68Ga-HER2-affibody and 18F-FDG PET/CT, HER2-TBR was higher than FDG-TBR in the HER2-low and HER2-positive group, respectively (P < 0.001). HER2-SUVmax and HER2-SUVmean exhibited differences across most comparisons, especially HER2-zero vs. -low (P < 0.05). HER2-SUVmean emerged as an independent predictor (P = 0.01; OR: 2.8) for differentiating HER2-low/positive and -zero, yielding an AUC of 0.91. Under detailed HER2 immunohistochemistry, HER2-SUVmax, -SUVmean and -TBR demonstrated intergroup differences (P < 0.05).

CONCLUSION

HER2-targeted PET/CT imaging demonstrated distinct advantages over 18F-FDG PET/CT imaging in characterizing the HER2 status of primary lesions. Parameters based on HER2-affibody differed significantly among different HER2 statuses, and might be potential imaging indicators for screening patients with HER2-low/positive who could benefit from HER2-targeted ADCs.

GOV IDENTIFIER: NCT06289517 (2024-03-04).

Для цитирования: Gao Yuan, Yin Lei, Duan Xiaojiang, Fu Zijian, Liu Qian, Chen Jinzhi, Xin Ling, Zhu Xiaojuan, Xiang Hongyu, Xu Ling, Ye Jingming, Liu Meng. HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.. European journal of nuclear medicine and molecular imaging. 2025. DOI: 10.1007/s00259-025-07220-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.